Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Ayoub, et al v. Spectrum Pharmaceuticals, Inc. et al
Case Number:
1:22-cv-10292
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
- Baker Botts
- Block & Leviton
- DiCello Levitt
- Kaplan Fox
- Katten Muchin
- Kirby McInerney
- Levi & Korsinsky
- Paul Hastings
- Pomerantz LLP
Companies
Sectors & Industries:
-
January 07, 2026
Kaplan Fox Remains Lead In Securities Suit After Ex-Client DQ
Kaplan Fox & Kilsheimer LLP will continue leading a putative securities class action against Spectrum Pharmaceuticals after a previously appointed lead plaintiff was removed from the case for allegedly going behind his lawyers' backs to push his own settlement plan and unrelated conspiracy theories.
-
August 05, 2025
Lead Kicked From Pharma Investor Case Over Rogue Emails
The lead plaintiff in a securities class action against Spectrum Pharmaceuticals in Manhattan federal court was removed from the case Tuesday when a federal judge found he broke confidentiality rules by going behind his lawyers' backs in an attempt to push his own settlement plan and fixating on unrelated conspiracy theories.
-
January 23, 2024
Pharma Co. Must Face Investor Suit Over Cancer Drug Study
Spectrum Pharmaceuticals must face a consolidated proposed securities class action alleging it misled investors about a lung cancer treatment drug study after a New York federal judge decided Tuesday that the suit adequately alleged the defendants "consciously or recklessly" made false or misleading statements.